New chemo cocktail aims to boost survival in elderly leukemia patients
NCT ID NCT06744556
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests two different chemotherapy combinations in adults aged 60-75 with acute myeloid leukemia (AML). One group gets a standard drug combo plus venetoclax (DAV/IAV), while the other gets a newer combo with homoharringtonine (HAV). The goal is to see which regimen leads to better event-free survival and remission rates. The study is active but not recruiting, with 41 participants enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy drugs (homoharringtonine, daunorubicin, idarubicin, cytarabine, venetoclax, azacitidine)
What this could lead to
If successful, this could identify a more effective chemotherapy combination for elderly AML patients, potentially improving remission rates and survival.
What could go wrong
This is a small, early-phase trial (41 participants) with no results yet. The new regimen may not be better than existing options and could have serious side effects like infection or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China